AR070558A1 - Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. - Google Patents
Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas.Info
- Publication number
- AR070558A1 AR070558A1 ARP090100362A ARP090100362A AR070558A1 AR 070558 A1 AR070558 A1 AR 070558A1 AR P090100362 A ARP090100362 A AR P090100362A AR P090100362 A ARP090100362 A AR P090100362A AR 070558 A1 AR070558 A1 AR 070558A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- cycloalkyl
- cycloalkyloxy
- lower alkyl
- alkyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) en donde R1 representa heterociclilo insustituido o sustituido, arilo insustituido o sustituido, cicloalquilo insustituido o sustituido; R2 representa hidrogeno, halogeno, alquilo inferior, alquiloxilo inferior, halo-alquilo inferior, cicloalquilo, cicloalquiloxilo, halo-cicloalquilo, cicloalquiloxilo, halo-cicloalquiloxilo; R3 representa hidrogeno, halogeno, alquilo inferior, alquiloxilo inferior, halo-alquilo inferior, cicloalquilo, cicloalquiloxilo, halo-cicloalquilo, cicloalquiloxilo, halo-cicloalquiloxilo; o R2 y/o R3 se conectan con R5 o R7 para formar una fraccion cíclica fusionada con el anillo de fenilo con el que R2/R3 están unidos; R2a representa hidrogeno, halogeno, alquilo inferior, alquiloxilo inferior, halo-alquilo inferior, cicloalquilo, cicloalquiloxilo, halo-cicloalquilo, cicloalquiloxilo, halo-cicloalquiloxilo; R3a representa hidrogeno, halogeno, alquilo inferior, alquiloxilo inferior, halo-alquilo inferior, cicloalquilo, cicloalquiloxilo, halo-cicloalquilo, cicloalquiloxilo, halo-cicloalquiloxilo; R4 representa un grupo -A1-N(R6)(R7) en donde A1 representa uno de los grupoide formulas (2) en donde el átomo marcado con * es un enlace con el anillo de fenilo; o R4 representa uno de los grupos de formulas (3); R5 representa, independientemente de cada otro hidrogeno, alquilo inferior, halo-alquilo inferior, cicloalquilo, halocicloalquilo o forma, junto con el átomo de carbono con el que está unido, un cicloalquilo; R6 y R7 representan, junto con el átomo de nitrogeno con el que están unidos, un heterociclo opcionalmente sustituido; o R6 representa hidrogeno o alquilo opcionalmente sustituido; y R7 representa alquilo opcionalmente sustituido; R8 representa alquilo, hidroxilo, alquiloxilo inferior, halo-alquiloxilo inferior, cicloalquiloxilo, halo-cicloalquiloxilo, alquilo inferior-sulfonilo, halo-alquilo inferior-sulfonilo, cicloalquil-sulfonilo, halo-cicloalquil-sulfonilo, alquilo inferior-sulfinilo, halo-alquilo inferior-sulfinilo, cicloalquil-sulfinilo, halo-cicloalquil-sulfinilo; R9 representa H o alquilo inferior; R10 representa hidrogeno, alquilo inferior, halo-alquilo inferior, cicloalquilo, halo-cicloalquilo; n representa 0, 1 o 2; o sales de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08151137 | 2008-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070558A1 true AR070558A1 (es) | 2010-04-21 |
Family
ID=39739330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100362A AR070558A1 (es) | 2008-02-06 | 2009-02-04 | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8420657B2 (es) |
| EP (1) | EP2247591A1 (es) |
| JP (1) | JP5323095B2 (es) |
| KR (2) | KR20130066703A (es) |
| CN (1) | CN101981036B (es) |
| AR (1) | AR070558A1 (es) |
| AU (1) | AU2009211338B2 (es) |
| BR (1) | BRPI0908433A2 (es) |
| CA (1) | CA2714177A1 (es) |
| CL (1) | CL2009000255A1 (es) |
| CO (1) | CO6321262A2 (es) |
| CR (1) | CR11614A (es) |
| DO (1) | DOP2010000242A (es) |
| EA (1) | EA017952B1 (es) |
| EC (1) | ECSP10010463A (es) |
| IL (1) | IL207224A0 (es) |
| MA (1) | MA32134B1 (es) |
| MX (1) | MX2010008719A (es) |
| NI (1) | NI201000137A (es) |
| NZ (1) | NZ587271A (es) |
| PA (1) | PA8815201A1 (es) |
| PE (1) | PE20091485A1 (es) |
| SM (1) | SMP201000104B (es) |
| TW (1) | TW200938202A (es) |
| UY (1) | UY31631A1 (es) |
| WO (1) | WO2009098236A1 (es) |
| ZA (1) | ZA201005338B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2009114533A2 (en) * | 2008-03-10 | 2009-09-17 | Cornell University | Modulation of blood brain barrier permeability |
| BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
| US8518933B2 (en) | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| EP2421870B1 (en) * | 2009-04-23 | 2016-03-09 | AbbVie Inc. | Modulators of 5-ht receptors and methods of use thereof |
| US8546377B2 (en) | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| CN102666545B (zh) * | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
| CN102711476B (zh) * | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| EA201291038A1 (ru) * | 2010-04-30 | 2013-05-30 | Целльзом Лимитид | Соединения пиразола в качестве ингибиторов jak |
| TW201204732A (en) | 2010-07-09 | 2012-02-01 | Leo Pharma As | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| EP2616538A4 (en) * | 2010-09-16 | 2014-03-05 | Univ Cornell | USE OF ADENOSINE RECEPTOR SIGNALS FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER |
| WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| CN103635189B (zh) | 2011-07-01 | 2016-05-04 | 诺华股份有限公司 | 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗 |
| KR20140063700A (ko) | 2011-09-20 | 2014-05-27 | 셀좀 리미티드 | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 |
| MX2014005927A (es) | 2011-11-15 | 2014-06-05 | Novartis Ag | Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2. |
| CN102627646A (zh) * | 2012-03-19 | 2012-08-08 | 苏州四同医药科技有限公司 | 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法 |
| CN102633802B (zh) * | 2012-04-11 | 2014-03-19 | 南京药石药物研发有限公司 | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 |
| WO2013170671A1 (zh) * | 2012-05-14 | 2013-11-21 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
| CN103059030B (zh) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
| EP3137468B1 (en) * | 2014-05-01 | 2021-10-06 | Novartis AG | Compounds and compositions as toll-like receptor 7 agonists |
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| CN111484496B (zh) * | 2019-01-29 | 2022-11-29 | 江苏开元药业有限公司 | 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途 |
| SG11202112362YA (en) | 2019-05-08 | 2021-12-30 | Vimalan Biosciences Inc | Jak inhibitors |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| KR20220051351A (ko) * | 2019-08-08 | 2022-04-26 | 비말란 바이오사이언스즈, 인크. | Jak 억제제 |
| GB201911868D0 (en) * | 2019-08-19 | 2019-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| EP4027993A4 (en) * | 2019-09-13 | 2023-09-20 | The Broad Institute Inc. | CYCLO-OXYGENASE 2 INHIBITORS AND THEIR USES |
| GB201914910D0 (en) * | 2019-10-15 | 2019-11-27 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN117043163A (zh) * | 2021-09-08 | 2023-11-10 | 希格生科（深圳）有限公司 | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 |
| CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
| CN116813624B (zh) * | 2023-06-29 | 2025-10-03 | 成都金瑞基业生物科技有限公司 | 一种jak2抑制剂的晶型及制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7917643B2 (en) * | 1996-09-12 | 2011-03-29 | Audible, Inc. | Digital information library and delivery system |
| US20030074530A1 (en) * | 1997-12-11 | 2003-04-17 | Rupaka Mahalingaiah | Load/store unit with fast memory data access mechanism |
| US6887224B2 (en) * | 1998-06-15 | 2005-05-03 | Ilse Rubio | Close fitting leakage resistant feminine hygiene pad |
| WO1999065908A1 (en) | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| GEP20053479B (en) | 1999-12-10 | 2005-03-25 | Pfizer Prod Inc | Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use |
| WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| MXPA04008592A (es) | 2002-03-07 | 2004-12-06 | Hoffmann La Roche | Inhibidores de piridina biciclica y pirimidina p38 cinasa. |
| US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
| US7532909B2 (en) * | 2003-10-15 | 2009-05-12 | Nextel Communications Inc. | System and method for providing dedicated paging channels for walkie-talkie services |
| US7319102B1 (en) | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
| DK1713806T3 (da) * | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
| JP2007526906A (ja) | 2004-03-05 | 2007-09-20 | 大正製薬株式会社 | ピロロピリミジン誘導体 |
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| AU2005298637B8 (en) * | 2004-10-29 | 2012-12-06 | Janssen Sciences Ireland Uc | HIV inhibiting bicyclic pyrimidine derivatives |
| US20060122003A1 (en) * | 2004-12-03 | 2006-06-08 | Kim Jong H | Portable golf swing position training aid kit |
| ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
| JP5227032B2 (ja) * | 2005-02-03 | 2013-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピリミジン |
| JP2006241089A (ja) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
| WO2006122003A2 (en) | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| US7749527B2 (en) | 2005-05-24 | 2010-07-06 | Wyeth Llc | Gel compositions for control of ecto-parasites |
| EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
| KR20080078668A (ko) | 2005-11-17 | 2008-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 융합된 바이사이클릭 ｍＴＯＲ 억제자 |
| ATE525374T1 (de) | 2005-12-13 | 2011-10-15 | Incyte Corp | Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren |
| WO2007109362A2 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| JP4861772B2 (ja) * | 2006-08-28 | 2012-01-25 | 富士通株式会社 | 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法 |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| KR20090033605A (ko) * | 2007-10-01 | 2009-04-06 | 삼성전자주식회사 | 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치 |
| WO2009070524A1 (en) | 2007-11-27 | 2009-06-04 | Wyeth | Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors |
| MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
| US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
-
2009
- 2009-02-04 AU AU2009211338A patent/AU2009211338B2/en not_active Ceased
- 2009-02-04 EA EA201001242A patent/EA017952B1/ru not_active IP Right Cessation
- 2009-02-04 NZ NZ587271A patent/NZ587271A/en not_active IP Right Cessation
- 2009-02-04 PE PE2009000162A patent/PE20091485A1/es not_active Application Discontinuation
- 2009-02-04 KR KR1020137011455A patent/KR20130066703A/ko not_active Withdrawn
- 2009-02-04 KR KR1020107019690A patent/KR101277823B1/ko not_active Expired - Fee Related
- 2009-02-04 CA CA2714177A patent/CA2714177A1/en not_active Abandoned
- 2009-02-04 WO PCT/EP2009/051281 patent/WO2009098236A1/en not_active Ceased
- 2009-02-04 AR ARP090100362A patent/AR070558A1/es not_active Application Discontinuation
- 2009-02-04 CN CN2009801117630A patent/CN101981036B/zh not_active Expired - Fee Related
- 2009-02-04 MX MX2010008719A patent/MX2010008719A/es active IP Right Grant
- 2009-02-04 JP JP2010545458A patent/JP5323095B2/ja not_active Expired - Fee Related
- 2009-02-04 UY UY031631A patent/UY31631A1/es not_active Application Discontinuation
- 2009-02-04 BR BRPI0908433A patent/BRPI0908433A2/pt not_active IP Right Cessation
- 2009-02-04 EP EP09708802A patent/EP2247591A1/en not_active Withdrawn
- 2009-02-05 CL CL2009000255A patent/CL2009000255A1/es unknown
- 2009-02-05 US US12/366,218 patent/US8420657B2/en not_active Expired - Fee Related
- 2009-02-05 TW TW098103755A patent/TW200938202A/zh unknown
- 2009-02-05 PA PA20098815201A patent/PA8815201A1/es unknown
-
2010
- 2010-07-26 IL IL207224A patent/IL207224A0/en unknown
- 2010-07-27 ZA ZA2010/05338A patent/ZA201005338B/en unknown
- 2010-07-29 CR CR11614A patent/CR11614A/es not_active Application Discontinuation
- 2010-08-04 DO DO2010000242A patent/DOP2010000242A/es unknown
- 2010-08-04 NI NI201000137A patent/NI201000137A/es unknown
- 2010-09-02 MA MA33139A patent/MA32134B1/fr unknown
- 2010-09-02 SM SM201000104T patent/SMP201000104B/it unknown
- 2010-09-06 EC EC2010010463A patent/ECSP10010463A/es unknown
- 2010-09-06 CO CO10110021A patent/CO6321262A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
| AR095823A1 (es) | Compuesto de ciclopropanamina y uso del mismo | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR093195A1 (es) | Composicion para el control de plagas que incluye un derivado de iminopiridina | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| MX2014002770A (es) | Nuevos derivados dihidroquinolina-2-ona. | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| MX2016015641A (es) | Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina. | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR067904A1 (es) | Derivados de piperazina-amida | |
| AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |